Back to results
US 11,440,970 B2Granted
Nicotine-binding antibodies
AssigneesAntidote Therapeutics, Inc., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
InventorsMatthew W. Kalnik, Thomas Thisted, Nicola Beltraminelli, Stéphanie Fallot, Zuzana Biesova, Steve Fuller, Mark G. Lesage, Paul Pentel
Life of this patent
Estimating the term…
Abstract
Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
Claims18
A nicotine-binding antibody or nicotine-binding fragment thereof, comprising the complementarity determining regions (CDRs) of a heavy chain sequence and a light chain sequence selected from;
- a. the heavy chain sequence of SEQ ID NO:
- 1 and the light chain sequence of SEQ ID NO:
- 2;
- b. the heavy chain sequence of SEQ ID NO:
- 3 and the light chain sequence of SEQ ID NO:
- 4;
- c. the heavy chain sequence of SEQ ID NO:
- 5 and the light chain sequence of SEQ ID NO:
- 6;
- d. the heavy chain sequence of SEQ ID NO:
- 7 and the light chain sequence of SEQ ID NO:
- 8;
- e. the heavy chain sequence of SEQ ID NO:
- 9 and the light chain sequence of SEQ ID NO:
- 10;
- f. the heavy chain sequence of SEQ ID NO:
- 11 and the light chain sequence of SEQ ID NO:
- 12;
- g. the heavy chain sequence of SEQ ID NO:
- 13 and the light chain sequence of SEQ ID NO:
- 14;
- h. the heavy chain sequence of SEQ ID NO:
- 15 and the light chain sequence of SEQ ID NO:
- 16;
- i. the heavy chain sequence of SEQ ID NO:
- 17 and the light chain sequence of SEQ ID NO:
- 18;
- j. the heavy chain sequence of SEQ ID NO:
- 19 and the light chain sequence of SEQ ID NO:
- 20.
27 more elements
Dependencies are inferred from the claim text.